Presentation is loading. Please wait.

Presentation is loading. Please wait.

Bayesian network meta-comparison of maintenance treatments for stage IIIb/IV non- small-cell lung cancer (NSCLC) patients with good performance status.

Published byDorothy O’Connor’ Modified over 6 years ago

Similar presentations

Presentation on theme: "Bayesian network meta-comparison of maintenance treatments for stage IIIb/IV non- small-cell lung cancer (NSCLC) patients with good performance status."— Presentation transcript:

1 Bayesian network meta-comparison of maintenance treatments for stage IIIb/IV non- small-cell lung cancer (NSCLC) patients with good performance status not progressing after first-line induction chemotherapy: Results by performance status, EGFR mutation, histology and response to previous induction  Pui San Tan, Gilberto Lopes, Sanchalika Acharyya, Marcel Bilger, Benjamin Haaland  European Journal of Cancer  Volume 51, Issue 16, Pages (November 2015) DOI: /j.ejca Copyright © 2015 The Authors Terms and Conditions

2 Fig. 1 Search strategy diagram for trials evaluating maintenance treatments in good performance status stage IIIb/IV non-small-cell lung cancer (NSCLC) patients not progressing after first-line induction based on Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) [34] guidelines. aAVAPERL [35,36] and ATLAS [37,38] were not included in the network meta-analysis as there was no common comparator arm with other included maintenance trials. European Journal of Cancer  , DOI: ( /j.ejca ) Copyright © 2015 The Authors Terms and Conditions

3 Fig. 2 Trials included in network meta-analysis evaluating maintenance treatments in good performance status stage IIIb/IV non-small-cell lung cancer (NSCLC) patients not progressing after first-line induction. Thicknesses of lines are proportional to the number of trials included in analyses. aIFCT-GFPC 0502 [17] was a three-arm trial comparing switch to erlotinib, continue gemcitabine and no maintenance. European Journal of Cancer  , DOI: ( /j.ejca ) Copyright © 2015 The Authors Terms and Conditions

4 Fig. 3 Overall survival by Eastern Cooperative Oncology Group (ECOG) performance status (PS) and epidermal growth factor receptor (EGFR) mutation status for maintenance treatments in good performance status stage IIIb/IV non-small-cell lung cancer (NSCLC) patients not progressing after first-line induction. Treatments were compared to no maintenance. aBayesian network estimates reported as hazard ratio (95% credible intervals in black and 95% predictive intervals in red). bSwitch pemetrexed [39] and continue pemetrexed [9,46] estimates were estimated from trials results within the nonsquamous population. cTKI estimates by PS were in a predominantly Caucasian population. TKI, tyrosine kinase inhibitors; HR, hazard ratio. European Journal of Cancer  , DOI: ( /j.ejca ) Copyright © 2015 The Authors Terms and Conditions

5 Fig. 4 Overall survival by histology and induction response for maintenance treatments in good performance status stage IIIb/IV non-small-cell lung cancer (NSCLC) patients not progressing after first-line induction. Treatments were compared to no maintenance. Estimate for switch docetaxel in the nonsquamous population was an indirect comparison compared to no maintenance computed from Karayama et al. [45] which compared switch docetaxel to continue pemetrexed. aBayesian network estimates reported as hazard ratio (95% credible intervals in black and 95% predictive intervals in red). bTKI estimates by histology and induction response were in a predominantly Caucasian population. cSwitch pemetrexed [39] and continue pemetrexed [9,46] estimates by induction response subgroups were estimated from trials results within the nonsquamous population. CR/PR, complete or partial response to previous induction; SD, stable disease post-induction; TKIs, tyrosine kinase inhibitors; HR, hazard ratio. European Journal of Cancer  , DOI: ( /j.ejca ) Copyright © 2015 The Authors Terms and Conditions

6 Fig. 5 Surface under the cumulative ranking (SUCRA) curve of overall survival by Eastern Cooperative Oncology Group (ECOG) performance status (PS), histology, and response to induction for maintenance treatments in good performance status stage IIIb/IV non-small-cell lung cancer (NSCLC) patients not progressing after first-line induction. As an illustration (solid line, PS 0 panel), switch to pemetrexed had 63% probability of being the best maintenance for overall survival (OS) benefit, 85% probability of being among two best maintenance, 94% probability of being among the three best, and >99% probability of being among the four best, with average of these cumulative rank probabilities represented by SUCRA 85.4%. Mid-point step intervals were taken for each rank on the x-axis [21]. SUCRA plots by epidermal growth factor receptor (EGFR) mutation were not illustrated as there were only two treatment comparisons. aSwitch to pemetrexed [39] and continue pemetrexed [9,46] estimates by performance status (PS) and induction response were estimated from trials results within the nonsquamous population. bTyrosine kinase inhibitor (TKI) estimates by PS, histology and induction response were in a predominantly Caucasian population. European Journal of Cancer  , DOI: ( /j.ejca ) Copyright © 2015 The Authors Terms and Conditions

Download ppt "Bayesian network meta-comparison of maintenance treatments for stage IIIb/IV non- small-cell lung cancer (NSCLC) patients with good performance status."

Similar presentations

James R. Rigas Comprehensive Thoracic Oncology Program

James R. Rigas Comprehensive Thoracic Oncology Program
First-Line TKI Use in EGFR Mutation-Positive NSCLC

First-Line TKI Use in EGFR Mutation-Positive NSCLC
Volume 18, Issue 6, Pages (September 2015)

Volume 18, Issue 6, Pages (September 2015)
Belani CP et al. ASCO 2009; Abstract CRA8000. (Oral Presentation)

Belani CP et al. ASCO 2009; Abstract CRA8000. (Oral Presentation)
Volume 60, Issue 5, Pages (November 2011)

Volume 60, Issue 5, Pages (November 2011)
Impact of Systematic EGFR and KRAS Mutation Evaluation on Progression-Free Survival and Overall Survival in Patients with Advanced Non–Small-Cell Lung.

Impact of Systematic EGFR and KRAS Mutation Evaluation on Progression-Free Survival and Overall Survival in Patients with Advanced Non–Small-Cell Lung.
Erlotinib-related skin toxicities: Treatment strategies in patients with metastatic non- small cell lung cancer  Yoshio Kiyohara, MD, Naoya Yamazaki, MD,

Erlotinib-related skin toxicities: Treatment strategies in patients with metastatic non- small cell lung cancer  Yoshio Kiyohara, MD, Naoya Yamazaki, MD,
Efficacy and Safety of Pemetrexed Maintenance Therapy versus Best Supportive Care in Patients from East Asia with Advanced, Nonsquamous Non-small Cell.

Efficacy and Safety of Pemetrexed Maintenance Therapy versus Best Supportive Care in Patients from East Asia with Advanced, Nonsquamous Non-small Cell.
An Open-Label, Multicenter, Randomized, Phase II Study of Cisplatin and Pemetrexed With or Without Cixutumumab (IMC-A12) as a First-Line Therapy in Patients.

An Open-Label, Multicenter, Randomized, Phase II Study of Cisplatin and Pemetrexed With or Without Cixutumumab (IMC-A12) as a First-Line Therapy in Patients.
Volume 79, Issue 1, Pages (January 2013)

Volume 79, Issue 1, Pages (January 2013)
Emerging treatment strategies in recurrent platinum-sensitive ovarian cancer: Focus on trabectedin  Andrés Poveda, Isabelle Ray-Coquard, Ignacio Romero,

Emerging treatment strategies in recurrent platinum-sensitive ovarian cancer: Focus on trabectedin  Andrés Poveda, Isabelle Ray-Coquard, Ignacio Romero,
Rosell R et al. Proc ASCO 2011;Abstract 7503.

Rosell R et al. Proc ASCO 2011;Abstract 7503.
Distinct Epidemiology and Clinical Consequence of Classic Versus Rare EGFR Mutations in Lung Adenocarcinoma  Zoltan Lohinai, MD, Mir Alireza Hoda, MD,

Distinct Epidemiology and Clinical Consequence of Classic Versus Rare EGFR Mutations in Lung Adenocarcinoma  Zoltan Lohinai, MD, Mir Alireza Hoda, MD,
Figure 1. (A) Forest plot of common odds ratios (adjusted for ECOG PS) for best overall response by a priori subgroups in patients with KRAS wild-type.

Figure 1. (A) Forest plot of common odds ratios (adjusted for ECOG PS) for best overall response by a priori subgroups in patients with KRAS wild-type.
Prognostic impacts of EGFR mutation status and subtype in patients with surgically resected lung adenocarcinoma  Kazuya Takamochi, MD, Shiaki Oh, MD,

Prognostic impacts of EGFR mutation status and subtype in patients with surgically resected lung adenocarcinoma  Kazuya Takamochi, MD, Shiaki Oh, MD,
Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.
Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor,

Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor,
Patient Case 1 Patient Case 1: PET/CT Scan.

Patient Case 1 Patient Case 1: PET/CT Scan.
Cost-Effectiveness of Pemetrexed Plus Cisplatin as First-Line Therapy for Advanced Nonsquamous Non-small Cell Lung Cancer  Robert Klein, MS, Catherine.

Cost-Effectiveness of Pemetrexed Plus Cisplatin as First-Line Therapy for Advanced Nonsquamous Non-small Cell Lung Cancer  Robert Klein, MS, Catherine.
Meta-analysis of randomised phase III clinical trials comparing EGFR tyrosine kinase inhibitor (TKI) shows that male patients with non-small cell lung.

Meta-analysis of randomised phase III clinical trials comparing EGFR tyrosine kinase inhibitor (TKI) shows that male patients with non-small cell lung.

Similar presentations

Ads by Google